MRI test using a special food-like tracer for pancreatic cyst surgery
Part of Cancer, Digestive system clinical trials.
This Phase 1 study tests a specialized MRI scan using a tracer (hyperpolarized 13C-pyruvate) in people who have pancreatic cysts and are scheduled for surgery or a cyst wall biopsy. The scan may help doctors better understand cyst-related biology while you receive standard surgical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a pancreatic cyst and are planning surgery or a cyst wall biopsy
- You can understand the study and sign written consent
- You are able to safely have an MRI (no MRI-blocking conditions or implants)
- You are not pregnant or breastfeeding, and you use birth control if you could get pregnant
- Your weight is 260 lbs or less
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a special MRI scan and blood tests to see if they can detect early pancreatic cancer in people with high-risk pancreatic cysts called IPMNs. It may help identify cancer earlier, when treatment is more likely to work.
This study uses scans to measure how common “fatty change” is in the pancreas. It then looks at whether fatty change is related to specific features of pancreatic cysts (and may also include healthy people).
This early-phase study tests a special MRI scan using C-13 pyruvate to help identify and understand gliomas (a type of brain tumor) in people with brain tumors going to surgery or biopsy. It may help doctors see tumor signals better before or around the time of your procedure.
This study is testing a new MRI technique that may help predict how well pancreatic cancer treatments will work. You would receive a special substance (called hyperpolarized pyruvate) during a standard MRI scan.
This early-phase study tests whether a special MRI scan with injected labeled “pyruvate” can act as a biomarker (a measurable sign) for advanced solid tumor activity. It may help doctors see tumor metabolism over time and better track how treatment is affecting cancer.
This study tests a new, harmless “disposable” setup for MRI scans to measure how pancreatic cancer treatments affect the body. It may help doctors get more accurate MRI measurements, so treatment response can be assessed better.
Hear when a new Pancreatic Cyst trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.